JP5677294B2 - 腎疾患の検査方法 - Google Patents
腎疾患の検査方法 Download PDFInfo
- Publication number
- JP5677294B2 JP5677294B2 JP2011518306A JP2011518306A JP5677294B2 JP 5677294 B2 JP5677294 B2 JP 5677294B2 JP 2011518306 A JP2011518306 A JP 2011518306A JP 2011518306 A JP2011518306 A JP 2011518306A JP 5677294 B2 JP5677294 B2 JP 5677294B2
- Authority
- JP
- Japan
- Prior art keywords
- podocalyxin
- urinary
- value
- cre
- urine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000017169 kidney disease Diseases 0.000 title claims description 52
- 238000010998 test method Methods 0.000 title claims description 18
- 230000002485 urinary effect Effects 0.000 claims description 85
- 210000002700 urine Anatomy 0.000 claims description 82
- 102000004401 podocalyxin Human genes 0.000 claims description 81
- 108090000917 podocalyxin Proteins 0.000 claims description 81
- 102000004169 proteins and genes Human genes 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 48
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 36
- 206010021263 IgA nephropathy Diseases 0.000 claims description 36
- 238000010837 poor prognosis Methods 0.000 claims description 29
- 229940109239 creatinine Drugs 0.000 claims description 26
- 238000011862 kidney biopsy Methods 0.000 claims description 25
- 238000004393 prognosis Methods 0.000 claims description 25
- 239000003550 marker Substances 0.000 claims description 19
- 230000024924 glomerular filtration Effects 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 16
- 230000001900 immune effect Effects 0.000 claims description 5
- 230000029142 excretion Effects 0.000 description 31
- 238000012216 screening Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 14
- 230000003907 kidney function Effects 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 7
- 206010061989 glomerulosclerosis Diseases 0.000 description 7
- 238000007689 inspection Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 208000020832 chronic kidney disease Diseases 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 210000003584 mesangial cell Anatomy 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- 239000013049 sediment Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000010908 decantation Methods 0.000 description 4
- 230000001434 glomerular Effects 0.000 description 4
- 229940099472 immunoglobulin a Drugs 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 230000005499 meniscus Effects 0.000 description 4
- 210000000557 podocyte Anatomy 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000002562 urinalysis Methods 0.000 description 4
- 230000036325 urinary excretion Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 231100000853 glomerular lesion Toxicity 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101000595198 Homo sapiens Podocalyxin Proteins 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000002784 sclerotic effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010055847 Haemorrhage urinary tract Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008529 pathological progression Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000010245 tubular reabsorption Effects 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
1.尿中ポドカリキシンと、1つ以上の他のマーカーとを組み合わせて使用することを特徴とする、腎疾患の検査方法。
2.他のマーカーが腎機能マーカーであることを特徴とする前項1に記載の腎疾患の検査方法。
3.腎機能マーカーが推算糸球体濾過量および/または尿蛋白である、前項1または2に記載の腎疾患の検査方法。
4.尿中ポドカリキシン値と他のマーカーの値とを用いてポドカリキシンインデックス値を算出し、ポドカリキシンインデックス値を指標として使用する、前項1〜3のいずれか1に記載の腎疾患の検査方法。
5.ポドカリキシンインデックス値が、尿中ポドカリキシン値を推算糸球体濾過量で除することにより得られる、前項4に記載の腎疾患の検査方法。
6.ポドカリキシンインデックス値が、尿中ポドカリキシン値に尿蛋白値を乗することにより得られる、前項4に記載の腎疾患の検査方法。
7.ポドカリキシンインデックス値が基準値より高い場合、腎生検が必要であると判定される、前項4〜6のいずれか1に記載の腎疾患の検査方法。
8.基準値が、IgA腎症の予後良好群および予後比較的良好群からなる被験者群から得られた値である、前項7に記載の腎疾患の検査方法。
9.他のマーカーにより予後不良群に該当しないと予め判定された被験者を対象とする、前項1〜8のいずれか1に記載の腎疾患の検査方法。
10.尿中ポドカリキシン値または1つ以上の他のマーカーの値の、いずれか1つ以上を尿中成分の値を用いて補正する、前項1〜9のいずれか1項に記載の腎疾患の検査方法。
11.尿中成分が、尿中クレアチニンである、前項10に記載の腎疾患の検査方法。
12.尿中ポドカリキシンの検出を免疫学的手法により行う、前項1〜11のいずれか1項に記載の腎疾患の検査方法。
13.尿中ポドカリキシンを検出するための抗ポドカリキシン抗体を含む、前項1〜12のいずれか1項に記載の検査方法のための検査用試薬。
14.抗ポドカリキシン抗体を用いて尿中ポドカリキシンを検出する試薬を含む、前項1〜13のいずれか1項に記載の検査方法のための検査用試薬キット。
<式> PCX/Cre:尿中ポドカリキシン***量(μg/g)=100×尿中ポドカリキシン濃度(ng/mL)÷尿中クレアチニン濃度(mg/dL)
GFR(男)=194×SCre(血清クレアチニン)^−1.094×age(年齢)^−0.287
GFR(女)=GRF(男)×0.739
本発明において、糸球体濾過量としては、推算糸球体濾過量(eGFR)を用いることが好ましい。尿中ポドカリキシン***量をeGFRで割り、インデックス値「(PCX/Cre)/eGFR」を算出する。インデックス値「(PCX/Cre)/eGFR」の算出は、ソフトウェアを用いてコンピュータにより行ってもよい。インデックス値「(PCX/Cre)/eGFR」を本発明の検査方法の指標として用いることができる。
ポドカリキシン濃度の測定には、2種類の抗ヒトポドカリキシンモノクローナル抗体を用いた。これらの2種類の抗体は、ヒトポドカリキシンの異なる2つのエピトープを各々認識し、それぞれ抗ヒトポドカリキシンモノクローナル抗体a(以下単に「抗体a」と称する)と、抗ヒトポドカリキシンモノクローナル抗体b(以下単に「抗体b」と称する)である。本実施例では、抗体a固相化マイクロタイタープレート(分割型マイクロプレートGF8高:Nunc社)と、西洋ワサビPeroxidase(以下「HRP」と略す)により標識化した抗体bを用いた。
<式> 尿中ポドカリキシン***量(μg/g)=100×尿中ポドカリキシン濃度(ng/mL)÷尿中クレアチニン濃度(mg/dL)
実施例1の方法により、IgA腎症患者28症例から得た尿検体について、尿中ポドカリキシン***量(PCX/Cre)を算出した。また、同じ尿検体から推算糸球体濾過量(eGFR:estimated glomerular filtrationrate)及び尿蛋白***量(尿蛋白/Cre)を測定・算出し、尿中ポドカリキシン***量と組み合わせてインデックス値を得、インデックス値の予後スクリーニングマーカーとしての意義を検討した。
Claims (7)
- 尿中ポドカリキシン値を推算糸球体濾過量で除することにより得られるポドカリキシンインデックス値、または、尿中ポドカリキシン値に尿蛋白値を乗することにより得られるポドカリキシンインデックス値を指標として使用することを特徴とする、腎疾患の検査方法。
- ポドカリキシンインデックス値が基準値より高い場合、腎生検が必要であると判定される、請求項1に記載の腎疾患の検査方法。
- 基準値が、IgA腎症の予後良好群および予後比較的良好群からなる被験者群から得られた値である、請求項2に記載の腎疾患の検査方法。
- 他のマーカーにより予後不良群に該当しないと予め判定された被験者を対象とする、請求項1〜3のいずれか1に記載の腎疾患の検査方法。
- 尿中ポドカリキシン値が尿中成分の値を用いて補正された値である、請求項1〜4のいずれか1項に記載の腎疾患の検査方法。
- 尿中成分が、尿中クレアチニンである、請求項5に記載の腎疾患の検査方法。
- 尿中ポドカリキシンの検出を免疫学的手法により行う、請求項1〜6のいずれか1項に記載の腎疾患の検査方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011518306A JP5677294B2 (ja) | 2009-06-10 | 2010-06-09 | 腎疾患の検査方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009139187 | 2009-06-10 | ||
JP2009139187 | 2009-06-10 | ||
PCT/JP2010/003836 WO2010143422A1 (ja) | 2009-06-10 | 2010-06-09 | 腎疾患の検査方法 |
JP2011518306A JP5677294B2 (ja) | 2009-06-10 | 2010-06-09 | 腎疾患の検査方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2010143422A1 JPWO2010143422A1 (ja) | 2012-11-22 |
JP5677294B2 true JP5677294B2 (ja) | 2015-02-25 |
Family
ID=43308685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011518306A Active JP5677294B2 (ja) | 2009-06-10 | 2010-06-09 | 腎疾患の検査方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20120164662A1 (ja) |
EP (1) | EP2442105B1 (ja) |
JP (1) | JP5677294B2 (ja) |
ES (1) | ES2530054T3 (ja) |
WO (1) | WO2010143422A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170146553A1 (en) * | 2009-06-10 | 2017-05-25 | Masanori Hara | Test method on renal diseases |
WO2011105474A1 (ja) * | 2010-02-26 | 2011-09-01 | デンカ生研株式会社 | 急性腎障害の検査方法 |
JP5988199B2 (ja) * | 2012-05-29 | 2016-09-07 | 学校法人順天堂 | IgA腎症診断法 |
ES2686542T3 (es) * | 2012-10-18 | 2018-10-18 | Metanomics Gmbh | Medios y procedimientos para determinar una cantidad normalizada de aclaramiento de un biomarcador de enfermedad metabólica en una muestra |
RU2019121662A (ru) * | 2016-12-16 | 2021-01-18 | Мерк Патент Гмбх | Способы использования галектин-3-связывающего белка, обнаруживаемого в моче, для мониторинга тяжести и прогрессирования волчаночного нефрита |
AU2018313853A1 (en) | 2017-08-08 | 2020-01-02 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008122410A (ja) * | 2000-10-27 | 2008-05-29 | Masanori Hara | 腎障害の検査方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE461616B (sv) | 1987-05-08 | 1990-03-05 | Biocarb Ab | Foerfarande och testsats vid diagnos av iga nefropati med bestaemning av fibronektin-iga-komplex |
JP2932837B2 (ja) * | 1992-06-25 | 1999-08-09 | 富士レビオ株式会社 | ヒトポドカリキシンの測定方法 |
US5804452A (en) * | 1995-04-27 | 1998-09-08 | Quidel Corporation | One step urine creatinine assays |
JP2000241431A (ja) | 1999-02-17 | 2000-09-08 | Nissho Corp | 免疫グロブリンa−フィブロネクチン複合体の免疫学的測定試薬および測定法 |
AU768020C (en) * | 1999-03-19 | 2005-05-12 | Fuso Pharmaceutical Industries, Ltd. | A method for detecting megsin protein and use thereof |
JPWO2002037099A1 (ja) | 2000-10-27 | 2004-03-11 | 国際試薬株式会社 | 腎障害の診断方法 |
ATE458199T1 (de) * | 2001-05-04 | 2010-03-15 | Biosite Inc | Diagnostische marker der akuten koronaren syndrome und ihre verwendungen |
US20050181451A1 (en) * | 2004-02-12 | 2005-08-18 | Bates Harold M. | Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants |
JP4599568B2 (ja) * | 2007-01-31 | 2010-12-15 | 国立大学法人 新潟大学 | 腎障害の検出方法 |
US20090068683A1 (en) * | 2007-06-11 | 2009-03-12 | Mayo Foundation For Medical Education And Research | Markers for preeclampsia |
WO2011105474A1 (ja) * | 2010-02-26 | 2011-09-01 | デンカ生研株式会社 | 急性腎障害の検査方法 |
-
2010
- 2010-06-09 EP EP10785954.8A patent/EP2442105B1/en active Active
- 2010-06-09 US US13/377,510 patent/US20120164662A1/en not_active Abandoned
- 2010-06-09 ES ES10785954.8T patent/ES2530054T3/es active Active
- 2010-06-09 WO PCT/JP2010/003836 patent/WO2010143422A1/ja active Application Filing
- 2010-06-09 JP JP2011518306A patent/JP5677294B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008122410A (ja) * | 2000-10-27 | 2008-05-29 | Masanori Hara | 腎障害の検査方法 |
Non-Patent Citations (2)
Title |
---|
JPN6010045638; 関根盛、 原正則: '腎障害の新しいマーカーについて-尿中ポドサイト,ポドカリキシンと臨床病理学的意義-' Ther.Res. Vol.29 No.11, 2008, p.1900-1904 * |
JPN7014003563; Yuji Sato: 'Urine Podocyte mRNAs Mark Progression of Renal Disease' J Am Soc Nephrol Vol. 20, 200905, pp. 1041-1052 * |
Also Published As
Publication number | Publication date |
---|---|
EP2442105B1 (en) | 2015-01-07 |
ES2530054T3 (es) | 2015-02-26 |
WO2010143422A1 (ja) | 2010-12-16 |
JPWO2010143422A1 (ja) | 2012-11-22 |
EP2442105A4 (en) | 2012-11-28 |
US20120164662A1 (en) | 2012-06-28 |
WO2010143422A9 (ja) | 2011-04-07 |
EP2442105A1 (en) | 2012-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5759372B2 (ja) | 糖尿病性腎症の検査方法 | |
EP1946107B1 (en) | Diagnosis and monitoring of chronic renal disease using ngal | |
US20140377786A1 (en) | Diagnosis and monitoring of chronic renal disease using ngal | |
Ix et al. | Urine fibrosis markers and risk of allograft failure in kidney transplant recipients: a case-cohort ancillary study of the FAVORIT trial | |
JP5677294B2 (ja) | 腎疾患の検査方法 | |
Liu et al. | Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: the optimal cut-off value for Chinese patients | |
Gul et al. | Urinary IL-18: a marker of contrast-induced nephropathy following percutaneous coronary intervention? | |
US20100234765A1 (en) | Diagnosis and monitoring of chronic renal disease using ngal | |
Liu et al. | Serum immunoglobulin G provides early risk prediction in immunoglobulin A nephropathy | |
Moriya et al. | Arteriolar hyalinosis is related to rapid GFR decline and long-standing GFR changes observed on renal biopsies in normo-microalbuminuric type 2 diabetic patients | |
WO2011105474A1 (ja) | 急性腎障害の検査方法 | |
JP7190165B2 (ja) | 慢性腎臓病罹患の可能性の判定のための方法 | |
Dyga et al. | Is adiponectin in children with immunoglobulin A vasculitis a suitable biomarker of nephritis in the course of the disease? | |
JP2020051911A (ja) | 心不全マーカー | |
JP6083937B2 (ja) | 急性腎障害の検査方法 | |
US20170146553A1 (en) | Test method on renal diseases | |
Odum et al. | Prognostic value of elevated cardiac troponin I levels in pre-dialysis chronic kidney disease patients without cardiac symptoms | |
WO2024159237A1 (en) | Assay and related methods, kits and devices | |
Abdeen et al. | Study of urine aquaporine-5 as a biomarker for diabetic nephropathy | |
Abdulameer et al. | NGAL as a biomarker in chronic kidney disease | |
El-Baroudy et al. | Selectivity Index and Urinary Retinal Binding Protein as Predictors of Steroid Responsiveness in Pediatrics Nephrotic Syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130531 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140715 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140902 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141215 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141226 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5677294 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |